

# THE EFFECT OF ACUTE LITHIUM AND AMI-193, A NEW 5HT<sub>2</sub> ANTAGONIST, ON APOMORPHINE-INDUCED PECKING IN PIGEON

T. Bagheri, Sh. Ejtemaei Mehr and Sh. Shamshirgaran

Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

**Abstract-** Intramuscular (IM) administration of apomorphine (a mixed D<sub>1</sub>/D<sub>2</sub> dopamine receptors agonist, 0.2-1.6 mg/kg) induced pecking, a stereotype behavior in pigeons in a dose-dependent manner. In this study the effect of lithium (Li<sup>+</sup>, 240 mg/kg, IM) and AMI-193 (a new 5-HT<sub>2</sub> antagonist, 0.003 mg/pigeon) on apomorphine-induced pecking (AIP) were investigated. This study showed that Li<sup>+</sup> and AMI-193 did not induce pecking by itself but administration of each of these agents before apomorphine increased and decreased the AIP (apomorphine 0.8 mg/kg) respectively whereas concomitant use of Li<sup>+</sup> (240 mg/kg IM) and AMI-193 decreased AIP significantly. These results suggested that 5-HT<sub>2</sub> antagonists inhibit the inhibitory effect of serotonin on the dopamine release in the raphe-striatal pathway but Li<sup>+</sup> can modulate dopamine and serotonin function by different mechanisms and decrease this effect. As a result, it is concluded serotonin can decrease the AIP through 5-HT<sub>2</sub> receptors indirectly by decrease the dopamine release.

*Acta Medica Iranica*: 40 (2): 109-114; 2002

**Key Words:** Pecking, serotonin receptors, apomorphine

## INTRODUCTION

Biochemical and pharmacological evidence indicates the existence of three different serotonin (5-HT) receptor families termed 5HT<sub>1</sub> (5HT<sub>1A</sub>, 5HT<sub>1B</sub>, 5HT<sub>1C</sub>, 5HT<sub>1D</sub>) relating to G protein (1), 5HT<sub>2</sub> (5HT<sub>2A</sub>, 5HT<sub>2B</sub>, 5HT<sub>2C</sub>, 5HT<sub>4</sub>) relating to phosphoinositol and 5HT<sub>3</sub> relating to ion channels (2-4). 5-HT receptors subtypes have been shown to be present in the basal ganglia (5). High to moderate levels of 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor binding sites and the corresponding mRNA are present in several forebrain areas including the basal ganglia and the limbic system. Thus, high levels of 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> binding sites are found in the caudate nucleus,

nucleus accumbens, olfactory tubercle and pyriform cortex (5). Although there is a good correlation between the distribution of 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> binding sites and respective mRNAs (6), the relative distribution of mRNA for 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors differs. Moderate levels of mRNA for both 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors have been detected in substantia nigra (SN), whereas the ventral tegmental area (VTA) contains mRNA for 5-HT<sub>2C</sub> but not 5-HT<sub>2A</sub> receptors (6-8). A large scientific literature exists concerning the role of different 5-HT receptor subtypes in the control of brain dopamine-mediated transmission, for example substantial evidence suggests that the functional status of the mesocorticolimbic dopamine (DA) system originating in the VTA is under a phasic and tonic inhibitory control by the 5-HT system that acts by stimulating 5-HT<sub>2C</sub> receptor subtypes (5).

Lithium (Li<sup>+</sup>) is the most specific drug used for the treatment and prevention of recurrent manic-depressive disorders (14-16). The molecular mechanisms related to the therapeutic action of Li<sup>+</sup> are not known, but determination of the neuronal effects of this ion may help to elucidate the regulation of neurotransmission and improve our understanding of the pathophysiological processes underlying affective disorders. Basic research on the action of Li<sup>+</sup> has focused on its effects on synaptic functions. Investigators have examined a variety of enzymes, ion channels and pumps, receptors and second messenger systems for possible sites of action of lithium (17,18).

Apomorphine activates both D<sub>1</sub> and D<sub>2</sub> dopamine receptors (9-11). It has been reported that apomorphine induces stereotyped behaviour in mice, rats and dogs as well as in pigeons (12,13) apparently pecking behaviour is centrally mediated and both D<sub>1</sub> and D<sub>2</sub> receptors are required to induce pecking (13).

According to these evidences and in order to study the interaction between serotonergic and dopaminergic transmission in the basal ganglia, we attempted to investigate the effect of acute administration of Li<sup>+</sup> and a new 5HT<sub>2A</sub> antagonist AMI-193, 8-[3-(4-fluorophenoxy) propyl]-1-phenyl-1,3,8-triazaspiro [4.5]decan-4-one (19) on pecking induced by apomorphine.

### Correspondence:

Sh. Ejtemaeimehr, Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences.

Tel: +98 021 6112304

Email: ejtemam@sina.tums.ac.ir

## MATERIALS AND METHODS

Pigeons of either sex weighing 200-400g were obtained from various local breeders. The animals were housed in groups of 3 or 4 in large cages, and maintained on a 12:12hr light : dark cycle. Standard food and water were freely available, except during the time of experiments.

All experiments performed between 9 am and 5 pm the birds were taken from their home cage and released in a testing cage (28×28×28) cm with three lateral walls covered with black paper sheets with dots (average of 5.5 dots/dm<sup>2</sup>), since dots elicit a strong pecking response to apomorphine injection (20). Animals were allowed to adapt for 30 min before the first injection. Observation started within one minute after the birds received apomorphine. The birds were all observed through a one way mirror by a single experimenter stationed in the room, thus minimizing disturbance of the pigeons, and apomorphine-induced pecking at the floor or side walls, pecking at their own plumage or toes, preening, drinking, wing-flapping, stretching one or both wings, body or head-shaking, yawning were observed. The number of pecking was counted by direct observation for 60 min after apomorphine injection. All drugs were injected into the leg muscle.


Apomorphine HCl ampules (TECHLOPHARM, Germany), (AMI-193) [8-[3-(4-Fluorophenoxy)propyl]-1-phenyl]-1,3,8-triazaspiro [4.5] decan-4-

one (Tocris Cookson, UK) 5HT<sub>2</sub> antagonist, Lithium chloride (Merck, Germany) was dissolved in distilled water and AMI-193 was dissolved in DMSO. The drugs were prepared immediately before use and were administered in a volume which contained Li<sup>+</sup> (240 mg/kg), AMI-193 (0.003 mg/pigeon). Apomorphine was diluted in water to prepare suitable dose and metabisulfate was added as an antioxidant.


**Statistical analysis:** The data expressed as the mean ± SEM were analyzed by one way analysis of variance (ANOVA) and least significant difference (LSD) for multiple comparison. Differences with p<0.05 were considered statistically significant.

## RESULTS


Injection of different doses of apomorphine (0.2-1.6 mg/kg) caused dose-dependent pecking behaviour in pigeons (Fig. 1). The maximum response was obtained with 1.6 mg/kg of the drug. Because of vomiting it was impossible to administer higher doses of apomorphine. Pretreatment of animals with 5HT<sub>2</sub> antagonist (0.003 mg/pigeon) 15 minutes before apomorphine injection increased the pecking response induced by apomorphine (0.8 mg/kg intra-muscularly) (Fig. 2). Pretreatment of animals with single dose of lithium (240mg/kg) and single dose of 5HT<sub>2</sub> antagonist (0.003 mg/pigeon) 15 minutes before apomorphine (0.8 mg/kg) decreased the pecking response induced by apomorphine (Fig. 3).



**Fig. 1.** Effects of Apomorphine (0.2 mg/kg) injection on pecking. Each line represents one case (n=5). The case marked with arrow was excluded from analyses



**Fig. 2.** Effects of 5HT2 plus Apomorphine (0.8 mg/kg) injection on pecking. Each line represents one case (n=5).



**Fig. 3.** Injection of Lithium (240 mg/kg) caused a significant ( $p < 0.05$ ) decrease in pecking caused by injection of apomorphine (0.8 mg/kg) alone and apomorphine + 5HT2 (0.003 mg/pigeon) after 60 minutes.

## DISCUSSION

We investigated the influence of acute  $\text{Li}^+$  and a new  $5\text{HT}_2$  antagonist on apomorphine induced pecking. Apomorphine induced pecking in pigeons dose dependently. Lithium produced no effect on pecking by itself. The  $5\text{HT}_2$  receptor antagonist AMI-193 (19) increased the number of pecking response induced by apomorphine.

5-Hydroxytryptamine has been identified in nerve terminal varicosities within the striatum using high resolution autoradiographic techniques (21). 5-HT containing neurons originating from the midbrain raphe nuclei innervate both the SN and the VTA. Neuroanatomical studies have shown a high density of 5-HT-immunoreactive fibers in both the substantia nigra pars compacta and substantia nigra pars reticulata, in addition to the VTA (22). Serotonergic terminals make synaptic contacts with both dopamine-containing and non-dopamine-containing neurons in the substantia nigra pars compacta (SNc), substantia nigra pars reticulata (SNr) and VTA (22). Several 5-HT receptor subtypes have been shown to be present in the basal ganglia. High to moderate levels of  $5\text{-HT}_{2A}$  and  $5\text{-HT}_{2C}$  receptor binding sites are present in several forebrain areas including the basal ganglia and limbic system. Moderate levels of mRNA for both  $5\text{-HT}_{2A}$  and  $5\text{-HT}_{2C}$  receptors have been detected in the SN, whereas the VTA contains mRNA for  $5\text{-HT}_{2C}$  but not  $5\text{-HT}_{2A}$  receptors (22).

There has been some controversy since past as to the function of 5-HT in the striatum since the neurotransmitter has been reported to have both excitatory and inhibitory effects (23). It has been shown that lesions of the medial raphe nucleus in rats produced an increase in striatal dopamine turnover, possibly mediated by an action through the SN (24-28). It means  $5\text{HT}_2$  antagonist (AMI-193) inhibits the serotonin system and thus releases the dopamine from this inhibition in the Raphe-striatal pathway disinhibition of the dopamine system (29-34).

In support of an inhibitory role for 5-HT the antagonists cyproheptadine, methysergide and metergoline have been shown to potentiate the behavioural effects of apomorphine and amphetamine in rats (35). Therefore the present study was undertaken in an attempt to elucidate the effect of (AMI-193) on dopamine release and it seems it was acting on 5-HT receptors located on the nerve terminals of dopamine neurones in the striatum to modulate dopamine release.

Lithium and  $5\text{HT}_2$  antagonist (AMI-193) decreased apomorphine induced pecking. It has been shown that Li inhibits the rise of cyclic AMP produced by the dopamine agonist in a synaptosomal

preparation (36). On the other hand in certain cells,  $D_2$  stimulation may activate phospholipase C which hydrolyses the membrane phospholipid, phosphatidyl inositol biphosphate ( $\text{PIP}_2$ ) which again increases inositol triphosphate ( $\text{IP}_3$ ) and intracellular calcium. Lithium treatment reduces the level of inositol in the brain through inhibition of inositol-1-phosphate (37) which could interfere with the resynthesis of  $\text{PIP}_2$  and thus influence the signalling mechanisms operating through the phosphoinositide system (38). Also Lithium has been reported to affect several serotonergic processes including synthesis, release and uptake of 5HT (38). As lithium increases serotonin release in the hippocampus (35) and short term administration of lithium increases the synthesis of 5-HT from tryptophan by the enzyme tryptophan hydroxylase, it also increases the transport of the 5-HT precursor, tryptophan in the hippocampus (38) and striatum (35). It has been shown that lithium administration increases tryptophan uptake into slices of rat striatum (35). As we know 5-Hydroxytryptamine (5-HT) has an inhibitory effect on dopamine release. As a result it is concluded that the inhibitory effect of Li and the new  $5\text{-HT}_2$  antagonist (AMI-193) on pecking induced by apomorphine is controlled by the mentioned mechanisms.

## REFERENCES

1. Hamon M, Gozlan H, Mestikawy S, Emerit MB, Bolanos F, Schechter L. The central  $5\text{HT}_{1A}$  receptors: pharmacological, biochemical, Functional, and regulatory properties. *Ann NY Acad Sci* 1990; 600: 114-29.
2. Hardman Joel G et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th edition. MacGraw Hill 1996; 249-63.
3. Jacobs BL, Azmittia Ec: Structure and function of the brain serotonin system. *Physiol Rev* 1992; 72: 165-229.
4. Ashby CR Jr, Jiang LH, Kasser RJ, WanjRY. Electrophysiological characterization of 5-Hydroxytryptamine receptors in the rat medial prefrontal cortex. *J Pharmacol EXP Ther* 1990; 252: 171-78.
5. Pazos A, Palacios JM. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. *Brain Res* 1985; 346: 205-30.

6. Pompeiano M et al. Distribution of the serotonin 5-HT<sub>2</sub> receptor family mRNA: comparison between 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors. *Mol Brain Res* 1994; 23: 163-178.
7. Eberle-Wang K et al. Pattern of expression of the serotonin 2C receptor messenger RNA in the basal ganglia of adult rats. *J Comp Neurol* 1997; 384: 233-247.
8. Abramowsky D et al. Localization of 5-hydroxytryptamine 2C receptor protein in human and rat brain using specific antisera. *Neuropharmacology* 1984; 34: 1635-45.
9. Stoof JC, Kebabian JW. Two dopamine receptors biochemistry, physiology and pharmacology. *Life Sci* 1984; 35: 2281-96.
10. Seeman, P. Brain dopamine receptors. *Pharmacol. Rev* 1980; 32: 229-313.
11. Creese I, Sibely DR, Hamblin M.W, Leff SE. The classification of dopamine receptors :relationship to radioligand binding. *Ann. Rev. Neurosci* 1983; 6: 43-71.
12. Cheng HC, Long JP. Dopaminergic nature of apomorphine induced pecking in pigeons. *Eur J Pharmacol* 1974; 26: 313-20.
13. Zarrindast MR, Amin R. The role of D<sub>1</sub> and D<sub>2</sub> receptors in apomorphine-induced pecking in chicks. *Psychopharmacol* 1992; 106(1): 67-70.
14. Goodwin FK, Ebert MH. In *Lithium: Its Role in Psychiatric Research and Treatment*, S. Gershon and B Shopsin, Eds. (Plenum, New York, 1973), p. 237.
15. Schou M. Lithium in psychiatric therapy and prophylaxis. *J. Psych. Res* 1968; 6: 67-95.
16. Prien R.F, Kupfer DJ, Mansky PA, Small JC, Tuason VB, Voss C B, Johnson WE. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH collaborative study group comparing lithium carbonate , imipramine and a lithium carbonate imipramine combination. *Arch Gen Psych* 1974; 41: 1096-1104.
17. Wood AJ, Goodwin GM. A review of the biochemical and neuropharmacological actions of lithium . *Psychol Med* 1987; 17: 597-600.
18. Emile D. Risby, MD, John K. Hsiao, MP, Hussein K. Manji, MP; Jose Bitran, MD, Frances Moses; Dong Feng Zhou , MD ; Willian Z . Potter, MD ,Ph D. *Archgen psychiatry* 1991; 48: 513-24.
19. Ismaiel et al. Antagonism of 1-(2, 5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5HT<sub>2</sub> versus 5HT<sub>1c</sub> selective antagonist. *J Med chem.* 1993; 36: 2519-25.
20. Brunelli M. Magni F, Moruzzi G, Musumeci D. Apomorphine pecking in the pigeon . *Archives of Italian Biology* 1975; 113:303-25.
21. Arluison M . and de la Manche IS. High resolution radioautographic study of the serotonin innervation administration of (3H) -5- Hydroxy tryptamine. *Neuroscience* 1980; 5 : 229-40.
22. Di Matteo V, De Blasi A, Di Giulio C, Esposito E. Role of 5-HT<sub>2C</sub> receptors. *Trends in Pharmacological Sciences* 2001; 22(5) :229-32.
23. Davies J. and Tongroech P. Neuropharmacological Studies on the nigrostriatal and raphe-Striatal System in the rat. *Eur J pharmacol* 1978; 51 :91-100.
24. Muramatsu M, Tamaki-Ohashi J, Usuki C, Araki H, Chaki S, Aihara H. 5HT<sub>2</sub> antagonists and minaprine block the 5HT-induced inhibition of dopamine release from rat brain striatal slices. *Eur J pharmacol* 1988; 153:89-95.
25. Ennis C, Kemp JD, Cox B. characterization of inhibitory 5-Hydroxy tryptamine receptors that modulate dopamine release in the striatum. *J .Neuro chem.* 1981; 36: 1515-20.
26. Andrews DW, Patrick RL and Barchas JD. The effect of 5-Hydroxytryptophane and 5-Hydroxytryptamine on dopamine synthesis and release in rat brain striatal synaptosomes. *J Neurochem* 1978; 30 : 465-470.
27. Fibiger HC, Miller JJ. An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus of the substantia nigra in the rat. *Neuroscience* 1977; 2 :975-987.
28. Olpe HR, Koella WP. The response of striatal cells upon stimulation of the dorsal and median raphe nuclei *Brain Res* 1977; 122:357-360.
29. Dray A, Davies J, Oakley NR, Tongroach P, Velluccis. The dorsal and medial raphe projections to the substantia nigra in the rat : electrophysiological ,biochemical and behavioural observations. *Brain Res* 1978; 151 : 431-442.

30. James TA, Starr MS. Rotational behaviour elicited by 5HT in the rat: evidence for an inhibitory role of 5-HT in the substantia nigra and corpus striatum. *J pharm pharmacol* 1980; 32 :196-200.
31. Vyedo L, Grenhoff J, Svensson TH .Ritanserlin, a 5HT<sub>2</sub> receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. *Psychopharmacology (Berl)* 1989; 98: 45-50.
32. Giambalvo CT, snodgrass SR. Biochemical and behavioural effects of serotonin neurotoxins on the nigro striatal dopamine system: comparison of injection sites. *Brain Res* 1978; 152 :555-566.
33. Kelland MD, Freeman AS, chiodo LA. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigro-striatal dopamine neurons. *J pharmacol Exp ther* 1990; 253:803-811.
34. Debell eroche js and Bradford HF. presynaptic control of the synthesis and release of dopamine from striatal synaptosomes: a comparison between the effects of 5-Hydroxy tryptamine, acetylcholine, and glutamate. *J Neuro chem.* 1980; 35:1227-Q34.
35. *J.science* vol 213,25 sep 1981 1529-1531:Lithium increases serotonin release and decreases serotonin receptors in the hippocampus.
36. Reches A, Ebstein R P, Belmaker R H. The differential effect of lithium on noradrenaline and dopamine-sensitive accumulation of cyclic AMP in guinea pig brain.*Psychopharmacol* 1978; 58,213-216.
37. Hallcher L M, Sherman W R. The effects of lithium ion and other agents on the activity of myoinositol-1-phosphatase from bovine brain. *J Bion chem.* 1980; 255 (10): 896-901.
38. Dehpour A R, Samini M, Aliebrahimi F and Chavoushzadeh M A.The effect of acute lithium and rubidium pretreatment on apomorphine-induced pecking in pigeons.*Pharmacology & Toxicology* 1998; 82:147-152.